66224-70-2Relevant articles and documents
Synthesis of unstable carbides Ag2C2n (n = 3, 4) and characterization via crystallographic analysis of their double salts with silver(I) trifluoroacetate
Hau, Sam C. K.,Mak, Thomas C. W.
, p. 902 - 905 (2014)
Two new silver(I) carbides, Ag2C6 and Ag 2C8, have been synthesized, and single-crystal X-ray analysis of their crystalline silver(I) trifluoroacetate complexes, Ag 2C6·8AgCF3CO2·6H 2O, 4(Ag2C6)·16AgCF3CO 2·14.5DMSO, and 2.5(Ag2C8) ·10AgCF3CO2·10DMSO, provides detailed information on the influence of ligand disposition and orientation of the all-carbon anionic ligands in the construction of multidimensional supramolecular structures, which are consolidated by argentophilic and weak inter-/intramolecular interactions.
Synthesis of trimethylsilylpropynoyl chloride
Medvedeva,Andreev,Safronova,Afonin
, p. 1463 - 1466 (2005)
Trimethylsilylpropynoic acid reacts with thionyl chloride to give a mixture of trimethylsilylpropynoyl chloride and 3-chloro-3-trimethylsilyl-2-propenoyl chloride whose ratio depends on the reaction conditions (temperature, reactant ratio). Dimethylformamide almost does not catalyze the reaction. Treatment of trimethylsilylpropynoic acid with oxalyl chloride in the presence of 0.04 equiv of DMF at room temperature ensures selective formation of trimethylsilylpropynoyl chloride (yield 80%).
One-pot synthesis of 3-(trimethylsilyl)propynamides
Medvedeva,Andreev,Safronova
, p. 1466 - 1470 (2010)
A highly efficient one-pot procedure was developed for the synthesis of 3-trimethylsilylpropynamides by acylation of amines with trimethylsilylpropynoyl chloride generated in situ. Selective N-acylation and N,O-bis-acylation of -amino alcohols with format
Phosphorescent proteins for bio-imaging and site selective bio-conjugation of peptides and proteins with luminescent cyclometalated iridium(iii) complexes
Shiu, Hoi-Yan,Chong, Hiu-Chi,Leung, Yun-Chung,Zou, Taotao,Che, Chi-Ming
, p. 4375 - 4378 (2014)
A new bio-conjugation reaction for site selective modification of proteins and peptides with phosphorescent iridium(iii) complexes has been developed; the Ir(iii)-modified proteins and peptides display long emission lifetimes and large Stoke shifts that can be used for bio-imaging studies.
COMPOUNDS AND METHODS OF USE
-
Page/Page column 195; 197, (2022/03/09)
Disclosed are heterocyclic compounds or their pharmaceutically acceptable salts with ferroptosis-inducing activity, Those compounds or their pharmaceutically acceptable salts can be used to treat cancer.
COMPOUNDS AND METHODS OF USE
-
Page/Page column 80-83; 90-92; 124; 125, (2021/03/05)
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
CATHEPSIN C INHIBITORS
-
Paragraph 0171-0174, (2020/01/24)
Disclosed are compounds, pharmaceutical compositions used for inhibiting cathepsin C without inhibiting epidermal growth factor receptor (EGFR).
COMPOUNDS AND METHOD OF USE
-
Paragraph 1435, (2019/09/06)
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS
-
Paragraph 0113-0115, (2019/01/04)
The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'b being H or a (C1-C6)alkyl group, -N(R"b)-SO2-, R"b being H or a (C1-C6)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of cancers, such as metastatic cancers.
INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION
-
Paragraph 0115, (2019/01/04)
The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'b being H or a (C1-C6)alkyl group, -N(R"b)-SO2-, R"b being H or a (C1-C6)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.
